Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$230.29 USD

230.29
164,452

-0.41 (-0.18%)

Updated Aug 29, 2024 03:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (175 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can LabCorp (LH) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

by Zacks Equity Research

LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.

LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis

by Zacks Equity Research

LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.

LabCorp's (LH) Base Testing Volume Grows, Costs Rise

by Zacks Equity Research

LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity

by Zacks Equity Research

Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.

LabCorp (LH) to Strengthen Laboratory Footprint in Japan

by Zacks Equity Research

LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.

LabCorp (LH) Partners HealthVerity to Grow in Drug Development

by Zacks Equity Research

According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.

LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test

by Zacks Equity Research

LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.

Strength Seen in LabCorp (LH): Can Its 3.7% Jump Turn into More Strength?

by Zacks Equity Research

LabCorp (LH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

LabCorp (LH) Rides on Innovations Amid Cost Constraints

by Zacks Equity Research

LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

LabCorp (LH) to Enhance Access to OmniSeq INSIGHT via New Program

by Zacks Equity Research

LabCorp's (LH) new sponsored lung cancer program will expand access to comprehensive genomic testing for NSCLC patients to guide informed treatment decisions.

LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients

by Zacks Equity Research

LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.

LabCorp (LH) Debuts At-home Collection Kit for Diabetes Testing

by Zacks Equity Research

LabCorp's (LH) at-home collection kit makes it effortless for consumers to understand their diabetes risk and health status using an innovative and approved collection device.

Here's Why You Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.

LabCorp (LH) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

LabCorp (LH) reports better-than-expected earnings for the first quarter, with robust sales within the Drug Development arm driving the top line.

LabCorp (LH) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of 3.91% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

by Urmimala Biswas

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Robust base business growth and notable launches are likely to have contributed to LabCorp's (LH) Q1 performance.

LabCorp (LH) Stock Moves -0.57%: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed the most recent trading day at $276.30, moving -0.57% from the previous trading session.

Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Gains But Lags Market: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed at $271.14 in the latest trading session, marking a +1.5% move from the prior day.

LabCorp (LH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed the most recent trading day at $264.88, moving +0.24% from the previous trading session.

LabCorp (LH) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

LabCorp (LH) closed the most recent trading day at $263.66, moving -1.99% from the previous trading session.